Physician profile
John B Checton
NPI 1962476416
$1,539.02
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $224 · 2021: $593.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $356.50 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $356.49 | 2019-2021 | |
| Boston Scientific Corporation | $155.94 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $138.66 | 2019-2020 | |
| Pfizer INC. | $137.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $122.69 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $103.89 | 2019 | |
| Abiomed | $42.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $34.60 | 2019-2020 | |
| Terumo Medical Corporation | $19.47 | 2019 | |
| Amgen INC. | $15.09 | 2019 | |
| Amarin Pharma, INC. | $14.81 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.26 | 2019 | |
| Portola Pharmaceuticals, LLC | $14.22 | 2019 | |
| Teleflex LLC | $12.39 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Checton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.